ATRA Stock Summary and Trading Ideas (Atara Biotherapeutics | NASDAQ:ATRA)

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.

Atara Biotherapeutics trades on the NASDAQ stock market under the symbol ATRA.

As of June 3, 2026, ATRA stock price declined to $9.47 with 83,748 million shares trading.

ATRA has a beta of 2.46, meaning it tends to be more sensitive to market movements. ATRA has a correlation of 0.04 to the broad based SPY ETF.

ATRA has a market cap of $85.33 million. This is considered a Micro Cap stock.

Last quarter Atara Biotherapeutics reported $516,000 in Revenue and -$.29 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.61.

In the last 3 years, ATRA traded as high as $63.38 and as low as $3.92.

The top ETF exchange traded funds that ATRA belongs to (by Net Assets): VTI, VXF, IWC, DCOR, DFAC.

ATRA has underperformed the market in the last year with a price return of +18.4% while the SPY ETF gained +28.7%. However, in the short term, ATRA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +92.9% vs +10.3% return in SPY. But in the last 2 weeks, ATRA shares have been beat by the market, returning +0.6% compared to an SPY return of +2.9%.

ATRA support price is $9.17 and resistance is $10.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATRA shares will trade within this expected range on the day.